Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female between 18 and 40 years of age at the time of screening~* Negative PPD skin test at screening.~* Subjects must have chest X-ray showing no evidence of pulmonary pathology.~* Female subjects of childbearing potential must have a negative serum pregnancy test at screening, must not be breast-feeding and are required to use adequate contraception from enrolment till 1 month after dose 3.~* Screening laboratory values must be within the laboratory normal ranges.~* Negative for human immunodeficiency virus-1 and 2 (HIV 1/2) antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody.~* Subjects must give written informed consent.~* Subjects must be willing to make all evaluation visits, be readily reachable by telephone or personal contact by the study site personnel and have a permanent address.~* Subjects' resting seated vital signs must be within the protocol-defined ranges.~Exclusion Criteria:~* History of prior Bacillus Calmette-Guérin (BCG) vaccinations.~* History of documented exposure to Mycobacterium tuberculosis.~* History of previous administration of experimental Mycobacterium tuberculosis vaccines or previous exposure to experimental products containing components of the experimental vaccine.~* History of employment in a healthcare facility in a capacity that had direct or indirect contact with TB patients.~* Administration of any immunoglobulins or any immunotherapy within the 3 months preceding the first dose of study vaccination, and/or any blood products within the 4 months preceding HIV screening, or planned administrations during the study period.~* Use of St. John's Wort within six months of the Day 0 visit or planned administrations during the study period.~* Participation in another experimental protocol and/or receipt of any investigational products within 30 days prior to Day 0.~* History of autoimmune disease or causes of immunosuppressive states.~* History of any acute or chronic illness or medication that, in the opinion of the Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.~* History of significant psychiatric illness.~* Current drug or alcohol abuse~* History of previous anaphylaxis or severe allergic reaction to vaccines or any other allergen.~* Subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.~* Any chronic drug therapy to be continued during the study period, with the exception of vitamins and/or dietary supplements (including mineral preparations such as calcium carbonate), herbal medications except St. John's Wort, birth control pills, anti-histamines for seasonal allergies, SSRIs (e.g. Prozac, Zoloft, Paxil), NSAIDs (e.g. aspirin, ibuprofen), and acetominophen.~* Chronic administration (defined as more than 14 days total) of immunosuppressants or other immune modifying drugs within six months prior to the first vaccine dose.~* History of chronic or intermittently recurring illnesses such as migraine headaches, diabetes, heart disease, and asthma.~* Current administration of anti-TB prophylaxis or therapy.~* History of administration of a live attenuated virus vaccine within 30 days of enrollment.~* History of administration of a subunit or killed vaccine within 14 days of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects receiving the low-dose antigen candidate TB vaccine
- Group B (Type: EXPERIMENTAL): Subjects receiving the high-dose antigen candidate TB vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).